Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.54 |
| ▸ | RAB9A | P51151 | 5/20 | 0.54 |
| ▸ | NPC1 | O15118 | 4/20 | 0.54 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL3599553 | 0.99 | CYP1A2 (0.58) | CYP1A2CYP2C19SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL465734 | 0.88 | CYP1A2 (0.67) | CYP1A2CYP2C19SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL3601769 | 0.84 | L3MBTL1 (0.54) | CYP1A2CYP2C19SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL3931386 | 0.84 | SMN1; SMN2 (0.62) | CYP1A2CYP2C19SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL4636472 | 0.84 | SMN1; SMN2 (0.62) | CYP1A2CYP2C19SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL2199922 | 0.83 | CYP1A2 (0.60) | CYP1A2CYP2C19SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL21911454 | 0.79 | CYP1A2 (0.49) | CYP1A2CYP2C19SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL4093041 | 0.78 | CYP1A2 (0.71) | CYP1A2CYP2C19SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL13879748 | 0.78 | SMN1; SMN2 (0.54) | CYP1A2CYP2C19SMN1; SMN2RAB9ANPC1 | |
| Bromide SCHEMBL7142285 | 0.77 | CYP1A2 (0.69) | CYP1A2CYP2C19SMN1; SMN2RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298340-A1 | Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | disclosed |
| US-20100298340-A1 | Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | disclosed |
| WO-2007120096-A1 | THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298340-A1 | Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies | GRN, MAPT, GUCY1B1 | CYP1A2 3908/4885CYP2C19 4589/4885SMN1; SMN2 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.